Trubion Pharmaceuticals, Inc. has signed an agreement to be acquired by Emergent BioSolutions, Inc. for approximately $96.8 million. Trubion stockholders will also receive one Contingent Value Right (CVR) per share, which will entitle the holder to receive cash payments based on the achievement of predefined milestones. The milestone payments could potentially reach $38.7 million over a 36-month period after closing, bringing the total price to as much as $135.5 million. The transaction is expec...